Recombinant BCG expressing the LTAK63 adjuvant improves a short-term chemotherapy schedule in the control of tuberculosis in mice

Recombinant BCG expressing the LTAK63 adjuvant improves a short-term chemotherapy schedule in the control of tuberculosis in mice

Tuberculosis (TB) is one of the deadliest infectious diseases around the world. Prevention is based on the prophylactic use of BCG vaccine, effective in infants but as protection wanes with time, adults are less protected. Additionally, chemotherapy requires the use of many antibiotics for several m...

Full description

Bibliographic Details
Main Authors: Monalisa Martins Trentini, Alex Issamu Kanno, Dunia Rodriguez, Lazaro Moreira Marques-Neto, Silas Fernandes Eto, Ana Marisa Chudzinki-Tavassi, Luciana Cezar de Cerqueira Leite
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Immunology
Subjects:
BCG
tuberculosis
recombinant BCG
rBCG-LTAK63
immunotherapy
immuno-therapeutic vaccine
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.943558/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.943558/full

Similar Items